Christopher Graham, MS

Senior Director, Health Economics

MS, Clinical Epidemiology and Health Services Research
Wake Forest University, Winston-Salem, NC

BS, Biology
University of North Carolina, Chapel Hill, NC

Christopher Graham, MS, is a Senior Director of Health Economics at RTI-HS and provides extensive knowledge and experience in health economics and outcomes research studies, including cost-effectiveness, cost-benefit, cost-minimization, and budget-impact modeling, as well as database analyses. Mr. Graham has developed partitioned survival analyses, decision-tree, Markov, and Monte Carlo simulation models across numerous therapeutic areas, including oncology (metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, pancreatic cancer, gastric cancer, follicular non-Hodgkin's lymphoma, advance melanoma, hepatocellular carcinoma, acute myeloid leukemia, multiple myeloma); dermatology (atopic dermatitis, psoriasis, psoriatic arthritis, ankylosing spondylitis); mental health (depression, schizophrenia); hereditary angioedema; myelofibrosis; osteoporosis; age-related macular degeneration; renal transplantation; human immunodeficiency virus; asthma; chronic pain; smoking cessation; and migraine. Results of his economic analyses have been used in publications (e.g., peer-reviewed manuscripts and presentations at scientific conferences) to support submissions to health care payer and regulatory agencies in the United States, Canada, Europe, and Australia and to enhance marketing activities. Mr. Graham is an expert programmer in Microsoft Excel and Visual Basic for Applications and also has experience working in Decision Analysis by TreeAge, SAS, R, and Stata. Mr. Graham has used his programming skills to develop stochastic models using a Bayesian approach to model uncertainty to produce detailed sensitivity analyses around model parameters such as cost-effectiveness acceptability curves and net benefit analyses. He is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).